Why the study?
Use of donation after circulatory death hearts is hindered by high rates of primary graft dysfunction from ischemia/reperfusion injury, prompting investigation into whether butyrate can restore cardiomyocyte metabolic function.
Does butyrate improve mitochondrial and metabolic recovery in adult human ventricular cardiomyocytes following ischemia/reperfusion?
Does butyrate improve mitochondrial and metabolic recovery in adult human ventricular cardiomyocytes following ischemia/reperfusion?
In a preclinical model, butyrate improved metabolic recovery and reduced apoptosis in human cardiomyocytes following ischemia/reperfusion, highlighting its potential to enhance donor heart viability for transplantation.
Butyrate merits testing in DCD heart models; leaves open whether metabolic rescue reduces primary graft dysfunction.
Background Cardiac transplantation is limited by a persistent shortage of donor organs. While hearts donated after circulatory death (DCD) could expand donors pool, their use is hindered by high rates of primary graft dysfunction (PGD) due to ischemia/reperfusion (I/R)-induced metabolic injury. Here, we investigate the therapeutic potential of the short-chain fatty acid butyrate (BT) to restore metabolic function in cardiomyocytes following I/R. Method Adult human ventricular cardiomyocytes were used for in vitro cell perfusion (IVCP). Following a period of warm ischemia, butyrate (BT) was introduced into a prechilled UW solution to mimic the standard in situ cold flush performed during heart explant. Cells were then reperfused with cultural media for 1h at 37°C, after which both cells and perfusate were harvested for spectrometric metabolite profiling and molecular analyses using standard methods. Results BT reprograms cardiac substrate use from glucose to BT, enhancing mitochondrial oxidative phosphorylation and ATP production, as evidenced by increased lactate clearance and upregulated mitochondrial BT-oxidation enzymes. This metabolic shift restores redox balance by elevating NAD+/NADPH pool and reducing ADP/ATP ratio, while suppressing histone deacetylation and promoting gene expression linked to mitochondrial biogenesis, damage repair, recycling, and turnover via enhanced mitofusion and PINK1/Parkin-mediated mitophagy. BT subsequently reduces mitochondrial ROS, enhances electron transport chain activity, and preserves oxidative phosphorylation, thereby lowering caspase-3/7 activity, preventing apoptosis, and promoting cardiomyocyte metabolic recovery. Conclusion BT restores mitochondrial and metabolic function, preserves ATP synthesis after I/R injury, and mitigates metabolic maladaptation, offering strong potential to improve cardiac viability, graft function, and transplantation outcomes. Graphical abstract Improving Cardiac Resilience to Ischemia/Reperfusion: The Role of Butyrate in Mitochondrial and Metabolic Recovery
No takes yet. Share an insight, caveat, or question.
Ruidas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: